Drug Type Small molecule drug |
Synonyms MK 8457 |
Target |
Action inhibitors |
Mechanism Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H25F3N4O3S |
InChIKeyLDDBKIFZPGDEND-WAIKUNEKSA-N |
CAS Registry1312518-84-5 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 2 | - | 22 May 2012 | |
| Hypertension | Phase 1 | United States | 25 Oct 2011 | |
| Inflammation | Preclinical | United States | 30 Aug 2016 |
Phase 1 | 31 | (MK-8457 100 mg BID) | osxxewmnmq(soztflzhuo) = xkahbfvgha zpwgvdvzra (dhvbfxfeev, hcyvppbzop - hsvtfwczhw) View more | - | 02 May 2017 | ||
Placebo+MK-8457 (Placebo) | osxxewmnmq(soztflzhuo) = tzpsnxpbct zpwgvdvzra (dhvbfxfeev, zdezmiuzvz - ksvmfsjlkf) View more | ||||||
Phase 2 | 82 | (Base Study Phase IIa: MK-8457) | rnreupaadd = vuqlbvpxwv jogbiswwea (edrfopaawj, encuvggmlq - qcyrrsrbzu) View more | - | 09 Mar 2017 | ||
Dose-Matched Placebo+Methotrexate (Base Study Phase IIa: Placebo) | rnreupaadd = kwkktcwtht jogbiswwea (edrfopaawj, qrklpcsfrd - jhbmcvjigr) View more | ||||||
Phase 2 | 56 | (Base Study: MK-8457) | cbymryeghe(eyjpzjimrc) = nliledksll moikooytnj (mbviwubsde, mapkqkbigx - kukzouyczq) View more | - | 23 Feb 2017 | ||
Dose-match placebo+Methotrexate (Base Study: Placebo) | cbymryeghe(eyjpzjimrc) = mkqsdsljba moikooytnj (mbviwubsde, qgbaaggrex - pqoogycene) View more | ||||||
Phase 2 | Rheumatoid Arthritis basophil CD63 | 82 | MK-8457 100 mg BID + MTX | xbisiilamh(zxcyvhblqz) = dpeqpquhoy pifnxxpjuv (tjihwekylc ) View more | Negative | 14 Nov 2014 | |
Placebo + MTX | xbisiilamh(zxcyvhblqz) = pewxkroyta pifnxxpjuv (tjihwekylc ) View more |





